^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    Apply
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/13/2019
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    PD-L1 • CD4
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit (NCT06805825)
    Phase 1
    Novelty Nobility, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    02/03/2025
    Primary completion :
    08/30/2027
    Completion :
    12/31/2027
    KIT
    |
    NN3201
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/22/2015
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) (NCT06026410)
    Phase 1
    Kura Oncology, Inc.
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/18/2023
    Primary completion :
    01/01/2027
    Completion :
    04/01/2027
    KRAS • NRAS • HRAS
    |
    KRAS mutation • HRAS mutation
    |
    Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • KO-2806
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2022
    Primary completion :
    02/20/2026
    Completion :
    02/20/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115
    Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (NCT03793166)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    06/07/2019
    Primary completion :
    09/15/2025
    Completion :
    09/15/2025
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (CK-301-101) (NCT03212404)
    Phase 1
    Checkpoint Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/20/2017
    Primary completion :
    11/18/2021
    Completion :
    12/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Unloxcyt (cosibelimab-ipdl)
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2009
    Primary completion :
    05/22/2019
    Completion :
    07/30/2025
    mTOR
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (NCT03473730)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    05/29/2018
    Primary completion :
    01/27/2025
    Completion :
    01/27/2025
    PD-L1
    |
    Darzalex (daratumumab)
    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCI-2018-01648) (NCT03682289)
    Phase 2
    Rahul Aggarwal
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/17/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    MSI • ATM • ARID1A • UGT1A1
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients (HPGD-ccRCC) (NCT06778538)
    Phase N/A
    Shang Panfeng
    Completed
    Last update posted :
    01/16/2025
    Initiation :
    07/01/2024
    Primary completion :
    11/01/2024
    Completion :
    11/20/2024
    HPGD
    Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) (NCT04267120)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    11/26/2024
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2024
    Completion :
    12/31/2025
    SDHB • TSC1
    |
    TSC1 deletion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (NCT03355976)
    Phase 2
    Brown University
    Active, not recruiting
    Last update posted :
    11/25/2024
    Initiation :
    04/30/2018
    Primary completion :
    03/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (NCI-2012-01247) (NCT01684397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    11/06/2024
    Initiation :
    11/21/2012
    Primary completion :
    05/02/2025
    Completion :
    05/02/2025
    CXCL8
    |
    Avastin (bevacizumab) • pazopanib
    MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO) (NCT02819596)
    Phase 2
    Queen Mary University of London
    Completed
    Last update posted :
    11/04/2024
    Initiation :
    05/03/2016
    Primary completion :
    07/17/2024
    Completion :
    07/17/2024
    PD-L1
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)
    [18F]PT2385 PET/CT in Patients with Renal Cell Carcinoma (NCT04989959)
    Phase 1
    Orhan Kemal Oz
    Recruiting
    Last update posted :
    11/01/2024
    Initiation :
    08/18/2021
    Primary completion :
    08/18/2026
    Completion :
    08/18/2027
    EPAS1
    Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (NCT03173560)
    Phase 2
    Eisai Inc.
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    08/17/2017
    Primary completion :
    02/14/2020
    Completion :
    06/30/2024
    PD-L1 • PD-1
    |
    everolimus • Lenvima (lenvatinib)
    A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) (NCT04028245)
    Phase 1
    Columbia University
    Recruiting
    Last update posted :
    07/09/2024
    Initiation :
    08/15/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    CD4
    |
    spartalizumab (PDR001) • Ilaris (canakinumab)
    Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) (NCT05665361)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    04/24/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    CD4
    |
    Ibrance (palbociclib) • sasanlimab (PF-06801591)
    Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (NCT02210117)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/03/2024
    Initiation :
    11/25/2014
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    IL17A
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • Beianting (bevacizumab biosimilar)
    Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-02) (NCT05520099)
    Phase N/A
    Elephas
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    06/26/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    MSI
    |
    MSI-H/dMMR
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    08/20/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-L1 • TP53 • PTEN • RB1
    |
    Yervoy (ipilimumab) • Ezharmia (valemetostat)
    NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER) (NCT05024318)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    02/08/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD8
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (CDFF332A12101) (NCT04895748)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    11/30/2021
    Primary completion :
    02/28/2025
    Completion :
    02/28/2025
    VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2
    |
    VHL mutation • SDHB mutation
    |
    everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    05/22/2019
    Primary completion :
    03/01/2023
    Completion :
    12/30/2024
    CRP
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (NCT05703854)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    03/29/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    PD-L1
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT05620134)
    Phase 1/2
    Salubris Biotherapeutics Inc
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    10/17/2022
    Primary completion :
    10/17/2025
    Completion :
    02/20/2026
    HER-2 • BRAF
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • SAL008
    Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT) (NCT05013099)
    Phase 2
    ImaginAb, Inc.
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    12/09/2021
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PD-L1 • KRAS • CD8 • PD-1
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression
    Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders (MITRIC) (NCT05286294)
    Phase 2
    Oslo University Hospital
    Recruiting
    Last update posted :
    04/04/2024
    Initiation :
    06/28/2022
    Primary completion :
    03/31/2034
    Completion :
    12/31/2034
    PD-L1 • MSI • LAG3
    |
    PD-L1 expression • MSI-H/dMMR
    A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT05706129)
    Phase 1/2
    Debiopharm International SA
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    03/14/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    EGFR
    |
    ITM-91
    Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy (REVOLUTION) (NCT03891485)
    Phase N/A
    National Cancer Institute, Naples
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    12/01/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    PD-L1 • IFNG • CD73 • IL10 • ENTPD1
    |
    Opdivo (nivolumab)
    Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) (NCT04779151)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/07/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2027
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD
    |
    HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    01/29/2019
    Primary completion :
    08/30/2024
    Completion :
    08/30/2024
    SETD2
    |
    SETD2 mutation
    |
    adavosertib (AZD1775)
    A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (NCT03972657)
    Phase 1/2
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/12/2019
    Primary completion :
    08/01/2025
    Completion :
    07/03/2026
    FOLH1
    |
    FOLH1 expression
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)
    Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer (ITHORinVHL) (NCT06195150)
    Phase N/A
    IRCCS San Raffaele
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    11/08/2023
    Primary completion :
    08/31/2024
    Completion :
    08/31/2024
    EPAS1
    ITIL-306 in Advanced Solid Tumors (NCT05397093)
    Phase 1
    Instil Bio
    Active, not recruiting
    Last update posted :
    03/05/2024
    Initiation :
    08/24/2022
    Primary completion :
    07/01/2025
    Completion :
    11/01/2039
    EGFR • KRAS • ALK • BRCA
    |
    BRCA mutation
    |
    cyclophosphamide • ITIL-306
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) (NCT04540705)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/11/2020
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    PD-L1
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib) • bempegaldesleukin (NKTR-214)
    A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166)
    Phase 1
    Exelixis
    Active, not recruiting
    Last update posted :
    02/19/2024
    Initiation :
    03/20/2019
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    HER-2 • KRAS • BRAF • NRAS • MSI
    |
    BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)